Internal Medicine Alert – February 28, 2015
February 28, 2015
View Issues
-
The Economic Burden of Undiagnosed Pre-diabetes
The economic burden of diagnosed and undiagnosed diabetes, gestational diabetes, and prediabetes has exceeded $322 billion.
-
Should Clinicians Discuss Resumption of Sexual Activity Following an Acute MI?
Although the U.S. and European cardiovascular society guidelines recommend that patients be counseled about resuming sexual activity after suffering an acute myocardial infarction (AMI), the actual demographics of sexual education post-myocardial infarction (MI) are unknown.
-
Treatment of C. Difficile — Follow the Guidelines
ABSTRACT & COMMENTARY: The primary outcome was the occurrence of complications, including relapse within four weeks, surgery, and 30-day mortality.
-
Edoxaban Tablets (Savaysa™)
The third oral factor Xa inhibitor has been approved by the FDA. Edoxaban is the fourth target-specific oral anticoagulant (TSOA) to enter the market following dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). Edoxaban is manufactured by Tokyo-based Daiichi Sankyo Company and marketed by Daiichi Sankyo as Savaysa.
-
Clinical Briefs
Topics: Metformin: Have we Been Overcautious in CKD?, Reduction in Prostate, and Doing the Right Thing for Acute Bronchitis in Healthy Adults: Antibiotics